Yakira Capital Management Inc. Makes New Investment in Inhibrx, Inc. (NASDAQ:INBX)

Yakira Capital Management Inc. acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 36,195 shares of the company's stock, valued at approximately $557,000. Yakira Capital Management Inc. owned about 0.25% of Inhibrx at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of INBX. Exchange Traded Concepts LLC purchased a new stake in Inhibrx in the 4th quarter valued at approximately $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in shares of Inhibrx in the 4th quarter valued at approximately $348,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Inhibrx in the fourth quarter valued at approximately $47,000. Rhumbline Advisers purchased a new stake in shares of Inhibrx in the fourth quarter valued at approximately $228,000. Finally, New York State Common Retirement Fund acquired a new position in Inhibrx during the fourth quarter worth $53,000. 82.46% of the stock is owned by institutional investors and hedge funds.

Inhibrx Stock Up 2.6 %

INBX stock traded up $0.30 during trading on Friday, reaching $11.62. 59,751 shares of the company were exchanged, compared to its average volume of 207,853. The stock's 50 day moving average price is $13.28 and its 200 day moving average price is $14.34. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $35.42.

Inhibrx (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The firm had revenue of $0.10 million during the quarter. On average, research analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

Remove Ads

Analysts Set New Price Targets

Separately, JMP Securities reissued a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.